AR074719A1 - Inhibidores de molecula pequena de lpxc , metodos de tratamiento y uso de los mismos - Google Patents

Inhibidores de molecula pequena de lpxc , metodos de tratamiento y uso de los mismos

Info

Publication number
AR074719A1
AR074719A1 ARP090103529A ARP090103529A AR074719A1 AR 074719 A1 AR074719 A1 AR 074719A1 AR P090103529 A ARP090103529 A AR P090103529A AR P090103529 A ARP090103529 A AR P090103529A AR 074719 A1 AR074719 A1 AR 074719A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
unsubstituted
group
independently selected
Prior art date
Application number
ARP090103529A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR074719A1 publication Critical patent/AR074719A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1) y las sales del mismo, en donde: A representa un radical cíclico divalente seleccionado a partir de cicloalquileno, arileno, o heteroarileno, cada uno de los cuales está sustituido con 0 a 4 residuos independientemente seleccionados a partir del grupo que consiste en hidrógeno, halógeno, alquilo C1-6, hidroxilo, alcoxilo C1-6, amino, mono- y di-alquilo C1-6-amino, y heterociclo de 5 a 7 miembros; R es hidrógeno, halógeno, hidroxilo, amino, o se selecciona a partir del grupo que consiste en alquilo C1-8, alquenilo C2-8, alquinilo C2-8, halo-alquilo C1-8, halo-alquenilo C2-8, halo-alquinilo C2-8, alcoxilo C1-8, halo-alcoxilo C1-8, hidroxi-alquilo C1-8, cicloalquil-alquilo C0-4, heterociclo-alquilo C0-4, cicloalquil-alcoxilo C0-4, heterociclo-alquiloxilo C0-4, COOH, CONH2, alcanoilo C1-8, alcoxilo C1-8-carbonilo, mono- y di-alquilo C1-8-amino, y fenil-alquilo C0-4, cada uno de los cuales está sustituido con 0 a 4 residuos independientemente seleccionados a partir del grupo que consiste en hidrógeno, halógeno, alquilo C1-6, hidroxi-alquilo C1-6, hidroxilo, oxo, alcoxilo C1-6, amino, mono- y di-alquilo C1-6-amino, y heterociclo de 5 a 7 miembros; R1 y R2, tomados en combinación con el átomo de carbono con el que están unidos, forman un anillo carbocíclico o heterocíclico de 3 a 7 miembros, el cual está insustituido o sustituido con 1. 2 ó 3 residuos seleccionados a partir de halógeno, hidroxilo, alquilo C1-4, o alcoxilo C1-4; o R1 es hidrógeno o alquilo C1-8; R2 se seleccione a partir del grupo que consiste en: a) -(CH2)rC(R2aR2b)(CH2)sOR5; b) -(CH2)rC(R2aR2b)(CH2)sNR6R7; c) -(CH2)rC(R2aR2b)(CH2)sN(R6)COR5; d) -(CH2)rC(R2aR2b)(CH2)sN(R6)CONR6R7; e) -(CH2)rC(R2aR2b)(CH2)sN(R6)C(=NH)NR6R7; f) -CHR2aR2b; g) -(CH2)rC(R2aR2b)CN; h) -(CH2)rC(R2aR2b)CO2R5; i) -(CH2)rC(R2aR2b)CONR6R7; en donde: cada presentación de R2a, R2b, R5, R6 y R7 se selecciona independientemente en cada presentación a partir del grupo que consiste en: a) hidrógeno; b) alquilo C1-6 sustituido o insustituido; c) halo-alquilo C1-6 sustituido o insustituido; d) aril-alquilo C0-4 sustituido o insustituido; e) cicloalquilo C3-7-alquilo C0-4 sustituido o insustituido; f) heterociclil-alquilo C0-4 sustituido o insustituido; y g) heteroaril-alquilo C0-4 sustituido o insustituido; o R6 y R7 geminales, tomados en combinación con el átomo de nitrógeno con el que están unidos, forman un anillo heterocíclico sustituido o insustituido que tiene de 3 a 8 átomos del anillo y de 1 a 3 heteroátomos del anillo independientemente seleccionados a partir del grupo que consiste en N, O ó S; o R2a y R2b, tomados en combinación con el átomo de carbono con el que están unidos, forman un anillo saturado, sustituido o insustituido, que tiene de 3 a 8 átomos del anillo y de 0 a 2 heteroátomos del anillo independientemente seleccionados a partir del grupo que consiste en N, O ó S; R3 es hidrógeno o alquilo C1-8; o R3 y R2, tomados en combinación con los átomos que intervienen, forman un anillo heterocíclico sustituido o insustituido que tiene de 3 a 8 átomos del anillo, y 0, 1 ó 2 heteroátomos adicionales del anillo independientemente seleccionados a partir de N, O ó S; R4 se selecciona a partir de OH, NH2 y NHOH; X1 y X2 se seleccionan independientemente a partir del grupo que consiste en O, S(O)q y NR8; R8 es hidrógeno, alquilo C1-8, cicloalquilo C3-8-alquilo C0-4, o alcanoilo C1-8; Y1 e Y2 se seleccionan independientemente a partir de los grupos alquileno C1-6 que están insustituidos o sustituidos una o más veces con R6; Y3 es un enlace o se selecciona a partir de los grupos alquileno C1-6 que están insustituido o sustituidos una o más veces con R6; Z está ausente, es -CR9=CR9 o etinileno; R9 se selecciona independientemente en cada presentación a partir del grupo que consiste en hidrógeno y alquilo C1-4; m y n se seleccionan independientemente a partir del grupo que consiste en 0, 1 y 2, en donde m + n es 1 ó 2; q es 0, 1 ó 2; y r y s se seleccionan independientemente a partir del grupo que consiste en 0, 1, 2, 3 y 4. Reivindicación 16: Un método para inhibir una enzima de desacetilasa en bacterias gram-negativas, comprendiendo el método el paso de poner en contacto las bacterias gram-negativas con un compuesto de la reivindicación 1. Reivindicación 24: El uso de un compuesto de la fórmula (1), de acuerdo con la reivindicación 1, para la preparación de un medicamento para el tratamiento de una infección bacteriana en un sujeto. Reivindicación 25: El uso de un compuesto de la fórmula (1), de acuerdo con la reivindicación 1, para la preparación de un medicamento para el tratamiento de una infección bacteriana gram-negativa en un sujeto.
ARP090103529A 2008-09-17 2009-09-15 Inhibidores de molecula pequena de lpxc , metodos de tratamiento y uso de los mismos AR074719A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9766408P 2008-09-17 2008-09-17

Publications (1)

Publication Number Publication Date
AR074719A1 true AR074719A1 (es) 2011-02-09

Family

ID=41397755

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103529A AR074719A1 (es) 2008-09-17 2009-09-15 Inhibidores de molecula pequena de lpxc , metodos de tratamiento y uso de los mismos

Country Status (13)

Country Link
US (1) US8372885B2 (es)
EP (1) EP2340241A1 (es)
JP (1) JP5550650B2 (es)
KR (1) KR20110055735A (es)
CN (1) CN102159537B (es)
AR (1) AR074719A1 (es)
AU (1) AU2009294710A1 (es)
CA (1) CA2737524A1 (es)
EA (1) EA201100505A1 (es)
MX (1) MX2011002804A (es)
TW (1) TW201018460A (es)
UY (1) UY32123A (es)
WO (1) WO2010031750A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5539864B2 (ja) * 2007-06-12 2014-07-02 アカオゲン，インコーポレーテッド 抗菌剤
CA2735929C (en) 2008-09-19 2013-12-17 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2011005355A1 (en) * 2009-05-07 2011-01-13 Achaogen, Inc. Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
JP5591494B2 (ja) * 2009-07-14 2014-09-17 東ソ−・エフテック株式会社 高純度の含フッ素エチリデン−２−メチルプロパンスルフィンアミド、その製造方法及びそれを用いた光学活性含フッ素アミン誘導体の製造方法
SI2512474T1 (sl) 2009-12-16 2014-12-31 Pfizer Inc. N-vezani derivati hidroksamske kisline, uporabni kot protibakterijska sredstva
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
DK2562155T3 (da) * 2010-04-20 2019-06-24 Fujifilm Toyama Chemical Co Ltd Hydroxaminsyrederivat
US9738604B2 (en) 2010-09-03 2017-08-22 Duke University Ethynylbenzene derivatives
SG192766A1 (en) 2011-03-07 2013-09-30 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
MX2013011432A (es) 2011-04-08 2013-12-09 Pfizer Derivados de imidazol, pirazol, y triazol utiles como agentes antibacterianos.
CN103717582B (zh) 2011-04-08 2015-09-30 辉瑞大药厂 用作抗菌剂的异*唑衍生物
JP6006609B2 (ja) * 2011-10-19 2016-10-12 大正製薬株式会社 新規なヒドロキサム酸誘導体を含有する医薬
JP5869311B2 (ja) * 2011-11-21 2016-02-24 国立大学法人 名古屋工業大学 光学活性含フッ素β−アミノ酸誘導体及びその製造法
WO2013170165A1 (en) 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
JP5902575B2 (ja) * 2012-07-20 2016-04-13 国立大学法人お茶の水女子大学 光学活性含フッ素アミン化合物の製造方法並びに光学活性含フッ素アミン化合物
RU2015112192A (ru) 2012-09-19 2016-11-10 Ф. Хоффманн-Ля Рош Аг 2-оксо-2,3,4,5-тетрагидро-1н-бензо[b]диазепины и их применение при лечении рака
WO2014165075A1 (en) 2013-03-12 2014-10-09 Achaogen, Inc. Antibacterial agents
ES2728336T3 (es) 2013-03-15 2019-10-23 Fujifilm Toyama Chemical Co Ltd Nuevo derivado de ácido hidroxámico o sal del mismo
WO2015024016A2 (en) 2013-08-16 2015-02-19 Duke University 2-piperidinyl substituted n,3-dihydroxybutanamides
WO2015024021A2 (en) 2013-08-16 2015-02-19 Duke University Antibacterial compounds
AU2014306451B2 (en) * 2013-08-16 2019-01-17 Duke University Substituted hydroxamic acid compounds
WO2016039432A1 (ja) 2014-09-12 2016-03-17 富山化学工業株式会社 新規なヒドロキサム酸誘導体および抗菌性物質を組み合わせて使用する方法
US10149911B2 (en) 2014-09-12 2018-12-11 Toyama Chemical Co., Ltd. Pharmaceutical composition containing hydroxamic acid derivative or salt thereof
CN105669750B (zh) * 2016-03-01 2018-04-03 中国医学科学院医药生物技术研究所 新型锌离子螯合剂及其制备和在抗革兰氏阴性菌感染中的应用
CA3022102A1 (en) * 2016-04-25 2017-11-02 Duke University Benzoylglycine derivatives and methods of making and using same
WO2017223349A1 (en) 2016-06-23 2017-12-28 Achaogen, Inc. Antibacterial agents
EP3820840A4 (en) * 2018-07-12 2022-04-27 Piramal Pharma Limited IMPROVED PROCESS FOR THE DIASTEREOSELECTIVE SYNTHESIS OF VICINAL DIAMINES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2709050A1 (de) 1976-06-10 1977-12-29 Eisai Co Ltd Neue hydroxamsaeurederivate und arzneimittel gegen harnstein und pyelonephrose, welche diese derivate enthalten
US6951884B2 (en) 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
MXPA05007394A (es) * 2003-01-08 2005-09-12 Chiron Corp Agentes antibacterianos.
BRPI0411412A (pt) 2003-06-13 2006-07-25 S A L V A T Lab Sa novas benzamidas como moduladores ppary
WO2007049729A2 (en) 2005-10-27 2007-05-03 Sumitomo Chemical Company, Limited Amide compounds and their use
JP5539864B2 (ja) * 2007-06-12 2014-07-02 アカオゲン，インコーポレーテッド 抗菌剤

Also Published As

Publication number Publication date
AU2009294710A1 (en) 2010-03-25
CN102159537A (zh) 2011-08-17
EA201100505A1 (ru) 2011-10-31
TW201018460A (en) 2010-05-16
KR20110055735A (ko) 2011-05-25
EP2340241A1 (en) 2011-07-06
US8372885B2 (en) 2013-02-12
WO2010031750A1 (en) 2010-03-25
JP5550650B2 (ja) 2014-07-16
CN102159537B (zh) 2014-11-05
MX2011002804A (es) 2011-04-11
UY32123A (es) 2010-04-30
JP2012502946A (ja) 2012-02-02
US20100120872A1 (en) 2010-05-13
CA2737524A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
AR074719A1 (es) Inhibidores de molecula pequena de lpxc , metodos de tratamiento y uso de los mismos
AR039413A1 (es) Derivados de n-(fenil(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica
BRPI0921701B8 (pt) Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende
AR080328A1 (es) Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
ATE349417T1 (de) 5-aminolaevulinsäure-ester als mittel zur photosensibilisierung in der chemotherapie
AR082275A1 (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
AR077974A1 (es) Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor
AR056347A1 (es) Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
PE20090510A1 (es) Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
BR112014015363A2 (pt) derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos
AR068055A1 (es) Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol su procedimiento de preparacion su aplicacion como medicamentos composiciones farmaceuticas y su utilizacion principalmente como inhibidores de met
AR069510A1 (es) Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10
AR070127A1 (es) Pirrolo - pirimidinas y pirrolo -piridinas
AR084433A1 (es) Inhibidores de la faah y composiciones farmaceuticas que los contienen
AR038863A1 (es) Uso de un inhibidor de garft y/o de aicarft y de un agente antitoxico para preparar un medicamento para destruir selectivamente celulas mtap-deficientes de un mamifero
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
PE20090238A1 (es) Derivados de pirazol como inhibidores de tirosinquinasas
BRPI0807597B8 (pt) composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação
AR072518A1 (es) Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met."
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros
BR112014000843A8 (pt) Uso de picosulfato para preparação de composição intestinal para o cálculo da duração de colonoscopia, composição intestinal e kit
BR112012011310A2 (pt) compostos derivados de 8-azabiciclo[3.2.1]octano-8-carboxamida, seu medicamento, seu agente terapêutico e seu uso
AR043444A1 (es) Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2

Legal Events

Date Code Title Description
FB Suspension of granting procedure